8-K: Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Instil Bio announced its Q4 and full year 2024 financial results, highlighting progress with AXN-2510/IMM2510 and providing a corporate update.

Summary

• Instil Bio reported its financial results for the fourth quarter and full year ended December 31, 2024.
• As of December 31, 2024, Instil had $115.1 million in total cash, cash equivalents, restricted cash, and marketable securities.
• The company believes this is sufficient to fund its operating plan beyond 2026.
• Research and development expenses were $1.1 million for the fourth quarter and $11.8 million for the full year 2024, compared to $2.0 million and $39.6 million for the same periods in 2023, respectively.
• General and administrative expenses were $10.4 million and $44.2 million for the fourth quarter and full year 2024, respectively, compared to $10.9 million and $47.6 million for the same periods in 2023, respectively.
• Net loss per share was $1.82 for the fourth quarter and $11.39 for the full year 2024, compared to $1.99 and $24.00 for the same periods in 2023, respectively.
• ImmuneOnco anticipates providing a clinical data update for AXN-2510/IMM2510 monotherapy in relapsed or refractory NSCLC in the first half of 2025.
• ImmuneOnco expects to begin enrolling first-line NSCLC patients in a Phase 1b/2 trial of AXN-2510/IMM2510 with chemotherapy in Q2 2025, with initial data expected in 2H 2025.
• Instil anticipates initiating a U.S. clinical trial of AXN-2510/IMM2510 in combination with chemotherapy for first-line NSCLC patients before the end of 2025, pending regulatory approvals.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the company's sufficient cash runway, progress in clinical trials, and potential milestones in the near term. However, the net loss and reliance on collaborators temper the overall positive outlook.

Positives

• Instil Bio's cash position of $115.1 million is expected to fund operations beyond 2026.
• Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC is anticipated in 1H 2025.
• Enrollment of first-line NSCLC patients in a trial of AXN-2510/IMM2510 and chemotherapy is anticipated to begin in Q2 2025.
• A U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in first-line NSCLC is anticipated before the end of 2025, assuming regulatory approvals.

Negatives

• The company experienced a net loss of $74.135 million for the full year 2024.
• Cash, cash equivalents, restricted cash, marketable securities and long-term investments decreased from $175.018 million in 2023 to $115.145 million in 2024.

Risks

• The company's future success depends on the clinical success and regulatory approval of its product candidates.
• The company relies on collaborators, including ImmuneOnco, for clinical trials and data generation, which introduces risks related to their performance.
• Macroeconomic conditions, including international conflicts and U.S.-China trade tensions, could adversely affect the business.
• The regulatory approval process is time-consuming and uncertain.
• The company faces competition from other companies developing similar therapies.

Future Outlook

Instil Bio expects its current cash resources to fund its operating plan beyond 2026 and anticipates several clinical milestones related to AXN-2510/IMM2510 in 2025.

Industry Context

The announcement highlights Instil Bio's focus on developing novel therapies, particularly in the competitive field of bispecific antibodies for cancer treatment. The company's collaboration with ImmuneOnco and the development of AXN-2510/IMM2510 position it within the broader trend of combining PD-L1 and VEGF inhibition for improved efficacy in solid tumors, especially NSCLC.

Comparison to Industry Standards

• Instil Bio's AXN-2510/IMM2510 is described as the 3rd-most advanced PD-(L)1xVEGF bispecific antibody in clinical development, suggesting that companies like Akeso/Summit (Ivonescimab) and BioNTech/Biotheus (BNT327) are ahead in the clinic.
• The company's strategy of combining PD-L1 and VEGF inhibition is consistent with the approach taken by other companies in the field, such as Merck (LM-299) and Crescent BioPharma.
• The company's focus on NSCLC aligns with the industry's recognition of this indication as a significant market opportunity for oncology therapies.
• The company's collaboration with ImmuneOnco in China mirrors the trend of Western biopharmaceutical companies partnering with Chinese firms to accelerate clinical development and access the Chinese market.

Stakeholder Impact

• Shareholders: The announcement provides an update on the company's financial performance and clinical development programs, which could influence investor sentiment.
• Employees: The company's financial stability and progress in clinical trials could positively impact employee morale and job security.
• Patients: The development of AXN-2510/IMM2510 could offer a new treatment option for patients with NSCLC and other solid tumors.
• Collaborators: The company's collaboration with ImmuneOnco is crucial for the development and commercialization of AXN-2510/IMM2510.

Next Steps

• ImmuneOnco will provide a clinical data update for AXN-2510/IMM2510 monotherapy in relapsed or refractory NSCLC in 1H 2025.
• ImmuneOnco will initiate enrollment of first-line NSCLC patients in a Phase 1b/2 trial of AXN-2510/IMM2510 with chemotherapy in Q2 2025.
• Instil Bio anticipates initiating a U.S. clinical trial of AXN-2510/IMM2510 in combination with chemotherapy for first-line NSCLC patients before the end of 2025, assuming regulatory approvals.
• File the Annual Report on Form 10-K for the year ended December 31, 2024 with the SEC.

Key Dates